Sulfonilamidothiopyrimidone and thiopyrimidone derivatives as selective COX-2 inhibitors: Synthesis, biological evaluation, and docking studies

European Journal of Medicinal Chemistry

Volumn 57, Issue , 2012, Pages 149-161

  Basile, Livia ^a   Álvarez, Susana ^b   Blanco, Almudena ^b   Santagati, Andrea ^c   Granata, Giuseppe ^c   Di Pietro, Patrizia ^c   Guccione, Salvatore ^a,c   Muñoz Fernández, M Ángeles ^b  

^a SCUOLA SUPERIORE DI CATANIA   (Italy)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Anti cancer; Anti inflammatory; COX 2; Human PBLs; PGE2; Thiopyrimidone derivatives

Indexed keywords

2 [[3 [(METHYLSULFONYL)AMINO] 4 OXO 6 PHENYL 3,4 DIHYDROTHIENO[2,3 D]PYRIMIDINYL]THIO]BENZOIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INTERLEUKIN 2; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N [2 [(2 NITROPHENYL)THIO] 4 OXO 6 PHENYLTHIENO[2,3 D]PYRIMIDIN 3(4H) YL]METHANESULFONAMIDE; N [2 [(2,4 DIFLUOROPHENYL)THIO] 4 OXO 6 PHENYLTHIENO[2,3 D]PYRIMIDIN 3(4H) YL]METHANESULFONAMIDE; N [2 [(4 NITROPHENYL)THIO] 4 OXO 6 PHENYLTHIENO[2,3 D]PYRIMIDIN 3(4H) YL]METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; SULFONILAMIDOTHIOPYRIMIDONE DERIVATIVE; THIOPYRIMIDONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFECT; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MOLECULAR DOCKING; MOLECULAR HYBRIDIZATION; PERIPHERAL LYMPHOCYTE; PROSTAGLANDIN RELEASE; T LYMPHOCYTE ACTIVATION;

BLOTTING, WESTERN; BROMODEOXYURIDINE; CATALYTIC DOMAIN; CELL DEATH; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; HUMANS; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MOLECULAR DOCKING SIMULATION; PYRIMIDINONES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; THERMODYNAMICS; THIADIAZOLES;

EID: 84866998506     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.09.005     Document Type: Article

References (35)

1. I.G. Colditz Margination and emigration of leucocytes Surv. Synth. Pathol. Res. 4 1985 44 68
2. T. Kasama, R.M. Strieter, T.J. Standiford, M.D. Burdick, and S.L. Kunkel Expression and regulation of human neutrophil-derived macrophage inflammatory protein 1 alpha J. Exp. Med. 178 1993 63 72
3. M. Gallin, K. Edmonds, J.J. Ellner, K.D. Erttmann, A.T. White, H.S. Newland, H.R. Taylor, and B.M. Greene Cell-mediated immune responses in human infection with Onchocerca volvulus J. Immunol. 140 1988 1999 2007
4. H. Ohshima, M. Tatemichi, and T. Sawa Chemical basis of inflammation-induced carcinogenesis Arch. Biochem. Biophys. 417 2003 3 11
5. W.L. Smith, and I. Song The enzymology of prostaglandin endoperoxide H synthases-1 and -2 Prostaglandins Other Lipid Mediat. 68-69 2002 115 128
6. J.R. Vane The fight against rheumatism: from willow bark to COX-1 sparing drugs J. Physiol. Pharmacol. 51 2000 573 586
7. L. Parente, and M. Perretti Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight Biochem. Pharmacol. 65 2003 153 159
8. K. Abouzid, and S.A. Bekhit Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity Bioorg. Med. Chem. 16 2008 5547 5556
9. Z. Feng, F. Chu, Z. Guo, and P. Sun Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib Bioorg. Med. Chem. Lett. 19 2009 2270 2272
10. J.M. Dogne, C.T. Supuran, and D. Pratico Adverse cardiovascular effects of the coxibs J. Med. Chem. 48 2005 2251 2257
11. I. Moodley Review of the cardiovascular safety of COXIBs compared to NSAIDS Cardiovasc. J. Afr. 19 2008 102 107
12. F.H. Sarkar, S. Adsule, Y. Li, and S. Padhye Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy Mini Rev. Med. Chem. 7 2007 599 608
13. M. Nivsarkar, A. Banerjee, and H. Padh Cyclooxygenase inhibitors: a novel direction for Alzheimer's management Pharmacol. Rep. 60 2008 692 698
14. A. Santagati, A. Marrazzo, and G. Granata Synthesis of potential selective COX-2 enzyme inhibitors derived from ethyl ester of 2-isothiocyanato-5-phenyl-3-thiophenecarboxylic acid J. Heterocyclic Chem. 40 2003 869 873
15. G. Dannhardt, and W. Kiefer Cyclooxygenase inhibitors - current status and future prospects Eur. J. Med. Chem. 36 2001 109 126
16. F. Russo, A. Santagati, M. Santagati, A. Caruso, S. Trombadore, and M. Amico-Roxas Synthesis and pharmacological properties of benzothienothiadiazolopyrimidine derivatives. III Farmaco Sci. 42 1987 437 447
17. A. Santagati, G. Granata, A. Marrazzo, and M. Santagati Synthesis and effects on the COX-1 and COX-2 activity in human whole blood ex vivo of derivatives containing the [1]benzothienol-[3, 2-d]pyrimidin-4-one heterocyclic system Arch. Pharm. (Weinheim) 336 2003 429 435
18. F. Russo, M. Santagati, A. Santagati, M. Amico-Roxas, R. Bitetti, and A. Russo [Chemical and pharmacological research on derivatives of 2,7-substituted 5H-1,3,4-thia(oxa)diazol[2,3-b]quinazolin-5-one] Farmaco Sci. 36 1981 292 301
19. F. Russo, M. Santagati, A. Santagati, and G. Blandino [Synthesis and antimycotic activity of derivatives of 1, 3, 4-thiadiazole (3,2a) pyrimidone] Farmaco Sci. 36 1981 983 993
20. R. Thomsen, and M.H. Christensen MolDock: a new technique for high-accuracy molecular docking J. Med. Chem. 49 2006 3315 3321
21. Molegro ApS, Hoegh-Guldbergs Gade 10, Bldg. 1090, DK-8000 Aarhus C, Denmark.
22. A.W. Schuttelkopf, and D.M. van Aalten PRODRG: a tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr. D Biol. Crystallogr. 60 2004 1355 1363
23. K.C. Duggan, M.J. Walters, J. Musee, J.M. Harp, J.R. Kiefer, J.A. Oates, and L.J. Marnett Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen J. Biol. Chem. 285 2010 34950 34959
24. C. Michaux, C. Charlier, F. Julemont, X. de Leval, J.M. Dogne, B. Pirotte, and F. Durant A new potential cyclooxygenase-2 inhibitor, pyridinic analogue of nimesulide Eur. J. Med. Chem. 40 2005 1316 1324
25. C. Michaux, X. de Leval, F. Julemont, J.M. Dogne, B. Pirotte, and F. Durant Structure-based pharmacophore of COX-2 selective inhibitors and identification of original lead compounds from 3D database searching method Eur. J. Med. Chem. 41 2006 1446 1455
26. C. McMartin, and R.S. Bohacek QXP: powerful, rapid computer algorithms for structure-based drug design J. Comput. Aided Mol. Des. 11 1997 333 344
27. M.A. Iniguez, C. Punzon, and M. Fresno Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors J. Immunol. 163 1999 111 119
28. A. Santagati, M. Modica, M. Santagati, A. Caruso, and V. Cutuli Synthesis of 2,3-dihydro-3-amino-6-phenyl-2-thioxothieno [2,3-d] pyrimidin-4 (1H)-one and of potential antiinflammatory agents 2-aryl-7-phenyl-3H, 9H-pyrimido [2,1-b]thieno-[2′,3′:4,5]]1,3,4] thiadiazin-9-ones Pharmazie 49 1994 64 65
29. G. Granata, S. Barbagallo, A. Perdicaro, A. Marrazzo, A. Santagati, L. Lombardo, and V. Cardile Synthetic approaches to bridgehead nitrogen methanesulfonamide derivatives of 3-amino-2-thioxo-2,3-dihydrothieno[2,3-d] pyrimidin-4(1H)-ones, potential COX-2 selective inhibitors J. Heterocyclic Chem. 43 2006 1099 1104
30. Y.M. Zhu, N.S. Azahri, D.C. Yu, and P.J. Woll Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells BMC Cancer 8 2008 218
31. K.G. Coggins, A. Latour, M.S. Nguyen, L. Audoly, T.M. Coffman, and B.H. Koller Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus Nat. Med. 8 2002 91 92
32. L.J. Mengle-Gaw, and B.D. Schwartz Cyclooxygenase-2 inhibitors: promise or peril? Mediators Inflamm. 11 2002 275 286
33. J.Y. Park, M.H. Pillinger, and S.B. Abramson Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases Clin. Immunol. 119 2006 229 240
34. V.C. Sandulache, A. Parekh, H. Li-Korotky, J.E. Dohar, and P.A. Hebda Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)-beta1-induced collagen synthesis Wound Repair Regen. 15 2007 122 133
35. B. Cryer, and M. Feldman Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs Am. J. Med. 104 1998 413 421